BridgeBio Pharma (BBIO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BBIO · Stock Price

USD 67.45+33.28 (+97.40%)

Market Cap: $13.1B

Historical price data

Market Cap: $13.1BPipeline: 3 drugsHQ: United States

Sector Ranking#13 in Rare & Orphan Diseases #96 in Small Molecule Drugs

Overview

BridgeBio Pharma is a clinical-stage biotech with a mission to translate genetic insights into life-changing medicines for rare diseases and cancers. The company has achieved significant milestones, including three FDA approvals, a robust late-stage pipeline with six Phase 3 trials conducted, and a market valuation reflecting strong investor confidence. Its core strategy leverages a decentralized hub-and-spoke operational model to pursue multiple high-precision programs simultaneously, targeting conditions with clear genetic etiology and significant unmet need.

Rare Genetic DiseasesOncology

Technology Platform

A genetics-first platform targeting diseases with clear monogenic drivers (mutations, missing enzymes, misfolded proteins) through multiple small-molecule modalities including stabilizers, enzyme enhancers, and allosteric modulators, accelerated by a hub-and-spoke operational model.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
BBP-398 + sotorasib	Solid Tumor, Adult	Phase 1
BBP-398 (Formerly known as IACS-15509)	Tumor, Solid	Phase 1
BBP-398 with nivolumab	Non Small Cell Lung Cancer	Phase 1

Funding History

4

Total raised:$868.5M

PIPE$250MViking Global InvestorsDec 15, 2020

IPO$348.5MUndisclosedJun 27, 2019

Series B$135MViking Global InvestorsJun 15, 2017

Series A$135MKKRJun 15, 2015

FDA Approved Drugs

1

ATTRUBYNDANov 22, 2024

Opportunities

BridgeBio's pipeline holds an estimated $8B peak sales potential, driven by first-in-class therapies for high-unmet-need rare diseases and a pioneering prevention trial for ATTR.

Global expansion and lifecycle management of core assets (e.g., encaleret in broader hypoparathyroidism) provide significant growth runways.

Risk Factors

Key risks include clinical/regulatory setbacks in late-stage trials, commercialization challenges in multiple niche rare disease markets simultaneously, high cash burn requiring continued financing, and operational complexity of the hub-and-spoke model.

Competition from alternative modalities like gene therapy also poses a long-term threat.

Competitive Landscape

BridgeBio competes in targeted segments: against other TTR stabilizers/silencers in ATTR, against BioMarin's Voxzogo in achondroplasia, and aims to be first-to-market in LGMD2I/R9 and ADH1. Its primary competitive advantage is its hub-and-spoke operational model, enabling faster, parallel development of genetically-precise therapies.